With a focus on the Psychiatry & Neurology and Oncology as priority disease areas, Sumitomo Pharma Group (the “Group”) will contribute to the betterment of healthcare and fuller lives of people worldwide through diverse approaches, including pharmaceutical products, regenerative medicine/cell therapy, and non-pharmaceutical solutions. In other areas, too, the Group will leverage its assets to deliver value to patients. With this, the Group aims to establish itself as a Global Specialized Player by 2033.
![Innovation today, healthier tomorrows](/assets/img/kv/lead01.webp)
![Innovation today, healthier tomorrows](/assets/img/kv/lead02.webp)
![](/assets/img/kv/img-loading.gif)
Showcase Sumitomo Pharma in a nutshell
Here you can search for the strengths of Sumitomo Pharma’s business, Sumitomo Pharma’s initiatives, and other information that interests you by selecting tags.
Strengths Sumitomo Pharma’s Three Strengths
- 1R&D Capabilities
- 2Human Resources
- 3Global Business Platforms
Sumitomo Pharma
Group Companies
Select area to see our subsidiaries information.
- -Japan
- -The United States
- -Asia
Chinese mainland
- Sumitomo Pharma (China) Co., Ltd.
- Sumitomo Pharma (Suzhou) Co., Ltd.
- Sumitomo Pharma Trading (Suzhou) Co., Ltd.
Taiwan
- Sumitomo Pharma Taiwan Co., Ltd.
Singapore
- Sumitomo Pharma Asia Pacific Pte. Ltd.
Thailand
Malaysia
- Sumitomo Pharma Malaysia Sdn. Bhd.
Vietnam
- The Representative Office of Sumitomo Pharma Asia Pacific Pte. Ltd. In Ho Chi Minh City
Sumitomo Pharma Co., Ltd.
Japan
Osaka
- Osaka Head Office
- Central Research Laboratories
- Osaka Research Center
Tokyo
- Tokyo Head Office
Kobe
- Regenerative & Cellular Medicine Kobe Center
The United States
Press Releases
- Aug. 30, 2024 Sumitomo Pharma Selected for Five Inclusions as a Constituent of GPIF-Adopted ESG Indexes Sustainability
- Aug. 07, 2024 Posted Conference on Q1 FY2024 Financial Results [Webcast] Finances
- Aug. 07, 2024 Sumitomo Pharma Announces Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan Products
- Aug. 07, 2024 【Joint press release】Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan Products
- Aug. 05, 2024 First Transplantation in Phase 1/2 Study of Allogeneic iPS Cell-Derived Retinal Pigment Epithelial Cells R&D
Notices
- Jun. 28, 2024 Consolidated Financial Statements for Years ended March 31, 2024 and 2023 Finances
- May 30, 2024 Posted Notice of Convocation of the 204th Annual Shareholders' Meeting Corporate
- Nov. 30, 2023 Posted Fact Book 2023 ver.2 Others
For the Press
Our latest press releases and other information for members of the press,
including various data sets and guidelines for their use.
-
Sustainability
Sumitomo Pharma defines the practice of its Mission, “To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide,” as Sustainability Management. To this end , Sumitomo Pharma is pursuing Sustainability Management through a variety of initiatives, including the development of innovative products and healthcare solutions, and contribution to the development of science.
-
About Us
Message from the President, corporate profile of Sumitomo Pharma, business activities, mid-term management plan, main offices and subsidiaries, etc.
-
Investor Relations
Information for shareholders and investors of Sumitomo Pharma, including management policies, IR materials, and stock and shareholder-related information.